Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Soloman Shah

Gastroenterology Fairfax, VA Medical Doctor

NPI 1578524997 CMS profile 161695

3700 Joseph Siewick Dr, Suite 401, Fairfax, VA 22033

Open in the dashboard

General payments

$7,089

433 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Soloman Shah of Fairfax, VA is reported in the CMS Open Payments database as having received $7,089 across 433 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 74th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,655 99
2024 General $1,496 105
2023 General $292 15
2022 General $1,399 72
2021 General $1,271 77
2020 General $551 35
2019 General $425 30

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Soloman Shah
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Soloman Shah were reported at $1,655. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Soloman Shah Gastroenterology median Middle half National median
2019 $425 $417 $126–$1,100 $163
2020 $551 $224 $74–$624 $114
2021 $1,271 $352 $106–$1,054 $132
2022 $1,399 $448 $129–$1,270 $149
2023 $292 $533 $150–$1,390 $160
2024 $1,496 $605 $160–$1,606 $164
2025 $1,655 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,719 117 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $1,167 75 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $714 54 payments
  4. Janssen Biotech, Inc. $524 28 payments
  5. Gilead Sciences, Inc. $421 17 payments
  6. Phathom Pharmaceuticals, Inc. $316 28 payments
  7. Celgene Corporation $302 23 payments
  8. Regeneron Healthcare Solutions, Inc. $224 9 payments
  9. Genzyme Corporation $185 8 payments
  10. Boston Scientific Corporation $158 3 payments
  11. Other $1,358 71 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,990 432 payments
  2. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. XIFAXAN $905 45 payments
  2. HUMIRA $625 39 payments
  3. ENTYVIO $562 43 payments
  4. RINVOQ $419 30 payments
  5. CREON $371 27 payments
  6. TRULANCE $337 34 payments
  7. STELARA $322 20 payments
  8. LINZESS $310 21 payments
  9. ZEPOSIA $302 23 payments
  10. TREMFYA $202 8 payments
  11. Other $2,771 162 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

523

Median for Gastroenterology: 569

Drug cost

$83,325

Median for Gastroenterology: $104,976

Branded share of claims

10.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xifaxan Rifaximin Brand 11 $62,696
Mesalamine Generic 14 $6,222
Cholestyramine Cholestyramine (With Sugar) Brand 28 $4,098
Sucralfate Generic 13 $3,360
Pantoprazole Sodium Generic 278 $2,815
Budesonide Dr Budesonide Brand 18 $2,279
Omeprazole Generic 59 $793
Famotidine Generic 90 $786
Lansoprazole Generic 12 $278

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$242,501

Of which drugs: $108,516

Medicare patients

672

Average age 73

Services billed

7,472

345 women, 327 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 31%
Diabetes 29%
Chronic kidney disease 26%
Heart failure 23%
Depression 22%
Atrial fibrillation 21%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, vedolizumab, 1 mg J3380 Office 11 4,200 $73,366
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 15 1,380 $34,507

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XIFAXAN
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $171
$171 11 —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $171
$171 — —
ENTYVIO
  • Takeda Pharmaceuticals U.S.A., Inc. $170
$170 — 4,200
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $112
  • GENZYME CORPORATION $53
$165 — —
TRULANCE
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $149
$149 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

433 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record